Apexigen
Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
31.Oct
2017

SAN CARLOS, Calif., Oct. 31, 2017 /PRNewswire/ — Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer with an emphasis on new Immuno-Oncology (I-O) agents, today announced that an abstract for Company’s lead I-O agent APX005M, a CD40 agonistic monoclonal antibody, was accepted as a late-breaking oral presentation at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be held November 8-12, 2017 in National Harbor, Maryland. The oral presentation titled First-in-human study with the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors (Abstract #O36) will be given on Friday, November 10, 2017 during the Clinical Trials: New Agents session (1:45 – 3:30 pm EDT) by Robert Vonderheide, M.D., DPhil, Director, Abramson Cancer Center of the University of Pennsylvania.

Six additional abstracts were accepted as poster presentations. These posters will detail the design of and rationale for ongoing clinical trials of APX005M, including Apexigen-sponsored trials and trials sponsored by the Parker Institute for Cancer Immunotherapy, The University of Texas MD Anderson Cancer Center, and the University of California San Francisco, as well as preclinical research.

About APX005M
APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response in the tumor microenvironment through antigen-presenting cells (APC) of the immune system. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 1/2 clinical development for the treatment of solid tumors.

Go to original source.